There was a lot of focus on the wording of the 6th DSMB report from February 26, 2018 regarding enrollment. However, I'd like to point out 3 additional documents that are more recent that reflect on enrollment.

1) March 19th, 2018: RESVERLOGIX EXCEEDS FULL ENROLLMENT FOR THE PIVOTAL PHASE 3 BETONMACE CLINICAL TRIAL. "Resverlogix announced today that it has successfully surpassed the planned enrollment target of over 2,400 patients in the ongoing Phase 3 BETonMACE trial......Achieving full enrollment early leaves two major clinical reflection points that will transpire in 2018."

2) June 14th, 2018: RESVERLOGIX ANNOUNCES FDA CONFIRMATION REGARDING FILING PATHWAY FOR APABETALONE. "The ongoing Phase 3 BETonMACE trial has enrolled its planned target of over 2,400 patients......BETonMACE is an event-driven trial, and with recruitment complete, continues to accumulate MACE towards the required number."

3) ERA-EDTA poster May 24-27, 2018: BETonMACE Chronic Kidney Disease Sub-Study: Effects of the Selective BET-Inhibitor Apabetalone on Kidney Function and MACE in Post-ACS Patients with Diabetes and Estimated Glomerular Filtration Rate Below 60. "To date, BETonMACE has randomized 2,416 patients of which 11% have screening eGFR below 60. At completion of the study, patients will have been treated from 6 to approximately 36 months." Abstracts for this meeting were due January 12, 2018. Posters are typically printed within a couple weeks of the meeting and often contain some info updated after abstract submission.

Since the Mar 19th news release of surpassing the 2400 patients came before the ERA-EDTA meeting, and the ERA-EDTA poster in late May had a number of 2416 patients, one interpretation of 1-3 above is the recruitment is now done, and final number is approximately 2416. Unlikely that the number of patients changed too much, if at all, in between the ERA-EDTA meeting in late May and the June 14th news release. Of course, this could change depending on whether or not they do a SSRA, and depending on the result of the potential SSRA (emphasis just for you GAC).

BearDownAZ